

Morten Ladekarl  
Clinical Professor, DMSc, MD  
Aalborg University Hospital  
Department of Clinical Medicine  
The Faculty of Medicine  
The Faculty of Medicine  
Klinik Kirurgi og Kræftbehandling  
Kræftbehandling (Onkologi)  
Email: morten.ladekarl@rn.dk, mla@dcm.aau.dk

## Employment

### Aalborg University Hospital

The Faculty of Medicine  
1 Jan 2019 → present

### Clinical Professor

Department of Clinical Medicine  
The Faculty of Medicine  
Aalborg, Denmark  
1 Jan 2019 → present

### Clinical Professor

The Faculty of Medicine  
Aalborg Øst, Denmark  
1 Jan 2019 → present

### The Faculty of Medicine

Aalborg Øst, Denmark  
1 Jan 2019 → present

### Professor

Department of Oncology  
The Faculty of Medicine  
1 Jan 2019 → present

## Research outputs

### Feasibility and early clinical impact of precision medicine for late-stage cancer patients in a regional public academic hospital

Ladekarl, M., Nøhr, A. K., Sønderkær, M., Dahl, S. C., Sunde, L., Vestereghem, C., Mapendano, C. K., Haslund, C. A., Pagh, A., Carus, A., Lörcincz, T., Nowicka-Matus, K., Poulsen, L. Ø., Laursen, R. J., Dybkær, K., Poulsen, B. K., Frøkjær, J. B., Brüggmann, A. H., Ernst, A., Wanders, A., & 2 othersBøgsted, M. & Pedersen, I. S., 11 Mar 2023, In: Acta Oncologica.

### ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling – a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial

Kringelbach, T., Højgaard, M., Rohrberg, K., Spanggaard, I., Laursen, B. E., Ladekarl, M., Haslund, C. A., Harsløf, L., Belcaid, L., Gehl, J., Søndergaard, L., Eefsen, R. L., Hansen, K. H., Kodahl, A. R., Jensen, L. H., Holt, M. I., Oellegaard, T. H., Yde, C. W., Ahlborn, L. B. & Lassen, U., 22 Feb 2023, In: BMC Cancer. 23, 1, 12 p., 182.

### Prediction and early diagnosis of immune-checkpoint inhibitor-induced inflammatory arthritis from molecular biomarkers – Where are we now?

Aboo, C., Krastrup, T. W., Tenstad, H. B., Ren, J., Just, S. A., Ladekarl, M. & Stensballe, A., 22 Dec 2022, In: Expert Review of Precision Medicine and Drug Development. 7, 1, p. 162-168

### **Onkologisk behandling – af cancer pancreatis**

Ladekarl, M., Weber, B., Jensen, B. V. & Pfeiffer, P., 1 Jul 2022, Version 1.2 ed. Danske Multidisciplinære Cancer Grupper. 27 p.

### **O-4 Trifluridine/tipiracil (TAS-102) with or without bevacizumab in patients with pretreated metastatic esophago-gastric adenocarcinoma (mEGA): A Danish randomized trial (LonGas)**

Pfeiffer, P., Yilmaz, M., Nordsmark, M., Möller, S., Elle, I., Ladekarl, M., Winther, S., Qvortrup, C. & Bæksgaard, L., Jun 2022, In: Annals of Oncology. 33, Suppl. 4, p. S380

### **Implementing a data infrastructure for precision oncology projects leveraging REDCap**

Vesteghem, C., Dahl, S. C., Brøndum, R. F., Sønderkær, M., Bødker, J. S., Schmitz, A., Weischenfeldt, J., Pedersen, I. S., Sommer, M., Rytter, A. S., Nielsen, M. M., Ladekarl, M., Severinsen, M. T., Dybkær, K., Grønbæk, K., El-Galaly, T., Roug, A. S. & Bøgsted, M., 12 May 2022, medRxiv, 20 p. (medRxiv).

### **Dansk Pancreas Cancer Database (DPCD) – Resumé af Årsrapport 2020/2021**

Styregruppen & Ladekarl, M., 24 Jan 2022, In: Ugeskrift for Læger. 2 p.

### **Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study**

Mouritzen, M. T., Junker, K. F., Carus, A., Ladekarl, M., Meldgaard, P., Nielsen, A. W. M., Livbjerg, A., Larsen, J. W., Skuladottir, H., Kristiansen, C., Wedervang, K., Schytte, T., Hansen, K. H., Østby, A-C., Frank, M. S., Lauritsen, J., Sørensen, J. B., Langer, S. W., Persson, G. F., Andersen, J. L., & 7 othersHomann, P. H., Kristensen, E. B., Drivsholm, L. B., Bøgsted, M., Christensen, H. S., Pøhl, M. & Bjørnhart, B., 2022, In: Acta Oncologica. 61, 4, p. 409-416 8 p.

### **Disparity in use of modern combination chemotherapy associated with facility type influences survival of 2655 patients with advanced pancreatic cancer**

Ladekarl, M., Rasmussen, L. S., Kirkegård, J., Chen, I., Pfeiffer, P., Weber, B., Skuladottir, H., Østerlind, K., Larsen, J. S., Mortensen, F. V., Engberg, H., Møller, H. & Frstrup, C. W., 2022, In: Acta Oncologica. 61, 3, p. 277-285 9 p.

### **Evaluation of SN-38 PK profile in patients with RAS wild-type metastatic colorectal cancer treated with a combination of SCO-101 and FOLFIRI. Journal of Clinical Oncology**

Schou, J. H. V., Roest, N., Ladekarl, M., Hansen, J. B. R., Hedtjaern, M. & Vestlev, P. M., 2022, In: Journal of Clinical Oncology. 40, Suppl. 4, 1 p., 185.

### **Prognostic significance of T-cell-inflamed gene expression profile and PD-L1 expression in patients with esophageal cancer**

Steiniche, T., Rha, S. Y., Chung, H. C., Georgsen, J. B., Ladekarl, M., Nordsmark, M., Jespersen, M. L., Kim, H. S., Kim, H., Fein, C., Tang, L. H., Wu, T., Marton, M. J., Peter, S., Kelsen, D. P. & Ku, G., Dec 2021, In: Cancer Medicine. 10, 23, p. 8365-8376 12 p.

### **Merkelcelle hudkræft**

Naseri, S., Fagmedarbejdere, Naseri, S., Chakera, A. H., Steiniche, T., Ladekarl, M., Mogensen, M. & Kjeldsen, H. C., 17 Nov 2021, sundhed.dk.

### **Merkelcelle karcinom**

Fagmedarbejdere, Naseri, S., Chakera, A. H., Steiniche, T., Ladekarl, M., Mogensen, M. & Kjeldsen, H. C., 17 Nov 2021, sundhed.dk.

### **Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC—Real World Efficacy**

Mouritzen, M. T., Carus, A., Ladekarl, M., Meldgaard, P., Nielsen, A. W. M., Livbjerg, A., Larsen, J. W., Skuladottir, H., Kristiansen, C., Wedervang, K., Schytte, T., Hansen, K. H., Østby, A-C., Frank, M. S., Lauritsen, J., Sørensen, J. B., Langer, S. W., Persson, G. F., Andersen, J. L., Frary, J. M. C., & 5 othersDrivsholm, L. B., Vesteghem, C., Christensen, H. S., Bjørnhart, B. & Pøhl, M., 28 Sep 2021, In: Cancers. 13, 19, 4846.

**Clinically decisive (dis)agreement in multidisciplinary team assessment of esophageal squamous cell carcinoma; a prospective, national, multicenter study**

Achiam, M. P., Nordmark, M., Ladekarl, M., Olsen, A., Loft, A., Garbyal, R. S., Larsen, M. H., Ainsworth, A. P., Kristensen, T. S., Dikinis, S., Kjær, D. W., Bæksgaard, L., Siemsen, M., Nielsen, M. B., Schlander, S., Kramer, S., Katballe, N., Kruhlikava, I., Tabaksblat, E., Fisker, R. V., & 6 othersMortensen, P. B., Holtved, E., Eckardt, J., Detlefsen, S., Naujokaite, G. & Lütken, C. D., Sep 2021, In: *Acta Oncologica*. 60, 9, p. 1091-1099 9 p.

**Folfinrox in the treatment of advanced gastroenteropancreatic neuroendocrine carcinomas**

Butt, B. P., Stokmo, H. L., Ladekarl, M., Tabaksblat, E. M., Sorbye, H., Revheim, M. E. & Hjortland, G. O., Sep 2021, In: *Annals of Oncology*. 32, 5, p. S915-S915 1108P.

**Merkelcellekarcinom**

Naseri, S., Steiniche, T., Ladekarl, M., Hölmich, L. R., Langer, S. W., Tabaksblat, E. M., Junker, N. & Chakera, A. H., 26 Jul 2021, In: *Ugeskrift for Læger*. 183, 3 p., V03210260.

**Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma**

Dyhl-Polk, A., Mikkelsen, M. K., Ladekarl, M. & Nielsen, D. L., 16 Jun 2021, In: *Journal of Clinical Medicine*. 10, 12, 2662.

**Patterns of Palliative Chemotherapy and Survival in Patients With Pancreatic Cancer Focusing on Age: A Nationwide Real-World Danish Registry Study**

Rasmussen, L. S., Frstrup, C. W., Jensen, B. V., Pfeiffer, P., Weber, B., Yilmaz, M. K., Poulsen, L. Ø., Ladekarl, M., Østerlind, K., Larsen, J. S., Skuladottir, H., Bøgsted, M. & Falkmer, U. G., 22 May 2021, In: *Pancreas*. 50, 5, p. 685-695 11 p.

**Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms**

Pommergaard, H. C., Nielsen, K., Sorbye, H., Federspiel, B., Tabaksblat, E. M., Vestermark, L. W., Janson, E. T., Hansen, C. P., Ladekarl, M., Garresori, H., Hjortland, G. O., Sundlöv, A., Galleberg, R., Knigge, P., Kjaer, A., Langer, S. W. & Knigge, U., May 2021, In: *Journal of Neuroendocrinology*. 33, 5, e12967.

**A phase II-study of electroporation potentiated immunotherapy in liver metastatic pancreatic cancer (EPIC-1)**

Flak, R. V., Poulsen, L. Ø., Stender, M. T., Naujokaite, G., Tcacenco, O., Wanders, A., Detlefsen, S., Agger, R., Kofod-Olsen, E., Thorlacius-Ussing, O. & Ladekarl, M., 2021, *Danske Kræftforskningsdage: Abstract Book*. p. 51 40

**Beskrivelse af den nationale MDT konference for pancreascancer: deltagelse og tilbud om operation**

Engberg, H., Møller, H., Hansen, C. P., Burgdorf, S., Fallentin, E., Frstrup, C. W., Jensen, B. V., Jensen, J. W., Knudsen, A. R., Ladekarl, M., Larsen, L. P. S., Mortensen, F. V., Kissmeyer-Nielsen, P., Sall, M., Stender, M. T., Storkholm, J. H., Gyllenborg, J. & Hillingsø, J., 2021, *Danske Kræftforskningsdage: Abstract Book*. p. 164 145

**Hans Jørgen Gottlieb Gundersen: 2.5.1943-1.2.2021**

Nyengaard, J. R., Ladekarl, M., Dorph-Petersen, K-A., Bendtsen, T. F., Nielsen, K. & Sørensen, F. B., 2021, In: *Ugeskrift for Læger*.

**Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC—Real World Efficacy**

Mouritzen, M. T., Carus, A., Ladekarl, M., Meldgaard, P., Nielsen, A. W. M., Livbjerg, A., Larsen, J. W., Skuladottir, H., Kristiansen, C., Wedervang, K., Schytte, T., Hansen, K. H., Østby, A-C., Frank, M. S., Lauritsen, J., Sørensen, J. B., Langer, S. W., Persson, G. F., Andersen, J. L., Frary, J. M. C., & 5 othersDrivsholm, L. B., Vesteghem, C., Christensen, H. S., Bjørnhart, B. & Pøhl, M., 2021.

**Scrotal Paget's disease associated with metastatic carcinoma with apocrine features and ERBB2-amplification/HER2 overexpression responding well to weekly paclitaxel combined with trastuzumab and pertuzumab. A case report**

Nowicka-Matus, K., Salkus, G., Pedersen, I. S., Sønderkær, M., Ernst, A., Takacs-Szabó, Z. & Ladekarl, M., 2021, *Danske Kræftforskningsdage: Abstract Book*. p. 152 133

### **Udredning og behandling af Cholangiocarcinom**

Larsen, P. N. (ed.), Rasmussen, A., Schultz, N., Mortensen, F. V., Knudsen, A. R., Stender, M. T., Sall, M., Pless, T., Vistisen, K., Larsen, F. O., Weber, B., Mortensen, H. R., Boysen, A. K., Ladekarl, M., Risum, S., Jensen, L. H., Fallentin, E., Willemoe, G., Hamilton, S., Kjær, M., & 4 others Grønbaek, H., Villadsen, G., Loft, A. & Schultz, L., 27 Oct 2020, Version 1.0 ed. Danske Multidisciplinære Cancer Grupper. 72 p.

### **Onkologisk behandling - af cancer pancreatis**

Ladekarl, M., Weber, B., Jensen, B. V. & Pfeiffer, P., 16 Oct 2020, Version 1.0 ed. Danske Multidisciplinære Cancer Grupper. 24 p.

### **PD-L1, tumor mutational burden, and overall survival among patients undergoing surgical treatment for hepatocellular carcinoma prior to systemic therapy**

Steiniche, T., Marsico, M. A., Siegel, A. B., Gronbaek, H., Ha, S., Hong, J. Y., Paik, Y-H., Georgsen, J., Pommergaard, H-CL., Ladekarl, M., Webber, A., Liu, X., Kachurak, A., Skaarup, K., Lee, J. & Lim, H. Y., 1 Sep 2020, In: Annals of Oncology. 31, Suppl. 4, p. S697 1006P.

### **Real word experience with first-line immunotherapy in advanced non-small cell lung cancer patients in a Danish nationwide cohort**

Mouritzen, M., Bjoernhart, B., Poehl, M., Ladekarl, M., Vesteghem, C., Boegsted, M., Nielsen, A. W. M., Meldgaard, P., Hansen, K. H., Larsen, J. W. W., Kristiansen, C., Wedervang, K., Bareid-Oestby, A-C., Frank, M. S., Persson, G., Kristensen, E. B., Homann, P. H. & Carus, A., 1 Sep 2020, In: Annals of Oncology. 31, Suppl. 4, p. S858 1 p., 1334P .

### **Targeting anti-cancer drug resistance in gastro-intestinal cancer: Inhibition of the SRPK1 kinase and degradation of the ABCG2 drug efflux pump**

Ladekarl, M., Schou, J. H. V., Roest, N. L., Stenvang, J., Brünner, N. & Vestlev, P. M., 1 Sep 2020, In: Annals of Oncology. 31, Suppl. 4, p. S503-S504 2 p., 605TIP .

### **Association of programmed death ligand 1 expression with prognosis among patients with ten uncommon advanced cancers**

Steiniche, T., Ladekarl, M., Georgsen, J. B., Andreasen, S., Busch-Sorensen, M., Zhou, W., Marton, M. J., Pruitt, S. K., Jin, F. & Liaw, K-L., 19 Aug 2020, In: Future Science OA. 6, 8, 11 p., FSO616.

### **International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis**

Díaz-González, Á., Sanduzzi-Zamparelli, M., Gomes da Fonseca, L. L., Di Costanzo, G. G., Alves, R., Iavarone, M., Leal, C., Sacco, R., Matilla, A. M., Hernández-Guerra, M., Aballay Soteras, G., Wörns, M-A., Pinter, M., Varela, M., Ladekarl, M., Chagas, A. L., Mínguez, B., Arenas, J. I., Granito, A., Sánchez-Torrijos, Y., & 29 others Rojas, Á., Rodríguez de Lope, C., Alvares-da-Silva, M. R., Pascual, S., Rimassa, L., Lledó, J. L., Huertas, C., Sangro, B., Giannini, E. G., Delgado, M., Vergara, M., Perelló, C., Lue, A., Sala, M., Gallego, A., Coll, S., Hernáez, T., Piñero, F., Pereira, G., França, A., Marín, J., Anders, M., Mello, V., Lozano, M., Nault, J. C., Menéndez, J., García Juárez, I., Bruix, J. & Reig, M., Jun 2020, In: Liver International. 40, 6, p. 1467-1476 10 p.

### **Tumor Ulceration, Reduced Infiltration of CD8-Lymphocytes, High Neutrophil-to-CD8-Lymphocyte Ratio and Absence of MC Virus are Negative Prognostic Markers for Patients with Merkel Cell Carcinoma**

Naseri, S., Steiniche, T., Georgsen, J. B., Thomsen, R., Ladekarl, M., Heje, M., Damsgaard, T. E. & Bønnelykke-Behrndtz, M. L., 6 Apr 2020, In: Cancers. 12, 4, p. 1-11 11 p., 888.

### **Initial treatment and survival in 4163 Danish patients with pancreatic cancer: A nationwide unselected real-world register study**

Rasmussen, L. S., Frstrup, C. W., Jensen, B. V., Pfeiffer, P., Weber, B., Yilmaz, M. K., Poulsen, L. Ø., Ladekarl, M., Østerlind, K., Larsen, J. S., Skuladottir, H., Hansen, C. P., Mortensen, M. B., Mortensen, F. V., Sall, M., Detlefsen, S., Bøgsted, M. & Falkmer, U. G., Apr 2020, In: European Journal of Cancer. 129, p. 50-59 10 p.

### **Pilot study experiences with hyperpolarized [1-13 C]pyruvate MRI in pancreatic cancer patients**

Stødkilde-Jørgensen, H., Laustsen, C., Hansen, E. S. S., Schulte, R., Ardenkjaer-Larsen, J. H., Comment, A., Frøkiaer, J., Ringgaard, S., Bertelsen, L. B., Ladekarl, M. & Weber, B., Mar 2020, In: Journal of Magnetic Resonance Imaging. 51, 3, p. 961-963 3 p.

**Acute pancreatitis as an early marker of pancreatic cancer and cancer stage, treatment, and prognosis**

Kirkegård, J., Gaber, C., Lund, J. L., Hinton, S. P., Ladekarl, M., Heide-Jørgensen, U., Cronin-Fenton, D. & Mortensen, F. V., Feb 2020, In: *Cancer epidemiology*. 64, 9 p., 101647.

**Management Recommendations for Merkel Cell Carcinoma-A Danish Perspective**

Naseri, S., Steiniche, T., Ladekarl, M., Bønnelykke-Behrndtz, M. L., Hölmich, L. R., Langer, S. W., Venzo, A., Tabaksblat, E., Klausen, S., Skaarup Larsen, M., Junker, N. & Chakera, A. H., Feb 2020, In: *Cancers*. 12, 3, 13 p., 554.

**PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3**

Ali, A. S., Langer, S. W., Federspiel, B., Hjortland, G. O., Grønbæk, H., Ladekarl, M., Welin, S., Weber Vestermark, L., Arola, J., Osterlund, P., Knigge, U., Sørbye, H., Micke, P., Grimelius, L., Grönberg, M. & Tiensuu Janson, E., 2020, In: *PLOS ONE*. 15, 12, e0243900.

**Upfront Surgery in Patients with High-Grade GEP NEN and MINEN: A Nordic Multicenter Study of 201 Patients**

Pommergaard, H. C., Nielsen, K., Sorbye, H., Federspiel, B., Tabaksblat, E., Vestermark, L., Tiensuu Janson, E., Hansen, C. P., Ladekarl, M., Garresori, H., Langer, S. & Knigge, U., 2020, *17th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, 11-13 March 2020, Barcelona, Spain, Virtual Conference*. p. 319

**Impact of Concurrent Acute Pancreatitis on Pancreatic Cancer Stage, Treatment, and Prognosis: A Study of Two Cohorts**

Kirkegård, J., Gaber, C., Lund, J. L., Peacock-Hinton, S., Ladekarl, M., Heide-Jørgensen, U., Cronin Fenton, D. & Mortensen, F. V., 3 Jun 2019.

**The effect of postoperative gemcitabine on overall survival in patients with resected pancreatic cancer: A nationwide population-based Danish register study**

Skau Rasmussen, L., Vittrup, B., Ladekarl, M., Pfeiffer, P., Karen Yilmaz, M., Østergaard Poulsen, L., Østerlind, K., Palnæs Hansen, C., Bau Mortensen, M., Viborg Mortensen, F., Sall, M., Detlefsen, S., Bøgsted, M. & Wilki Frstrup, C., Jun 2019, In: *Acta Oncologica*. 58, 6, p. 864-871 8 p.

**A multicenter international study of sorafenib treatment in patients with hepatocellular carcinoma and chronic kidney disease undergoing hemodialysis**

Diaz-Gonzalez, A., Sanduzzi-Zamparelli, M., Gomes da Fonseca, L., Di Costanzo, G. G., Alves, R., Iavarone, M., Leal, C. R. G., Sacco, R., Matilla, A. M., Guerra, M. H., Aballay Soteras, G. A., Marcus, W., Pinter, M., Varela, M., Ladekarl, M., Lopes Chagas, A., Minguez, B., Ignacio Arenas Ruiz-Tapiador, J., Granito, A., Sánchez, Y., & 29 othersRojas, A., Rodriguez De Lope, C., Reis Álvares-Da-Silva, M., Pascual, S., Rimassa, L., Luis Lledó, J., Huertas, C., Sangro, B., Giannini, E. G., Delgado, M., Vergara Gómez, M., Perello, C., Lué, A., Sala, M., Gallego Moya, A., Coll, S., Hernaez Alsina, T., Pinero, F., Pereira, G., Vianey Callado França, A., Callado França, V., Margarita Anders, M., Mello, V., Del Mar Lozano, M., Charles Nault, J., María Menéndez, J., Garcia Juarez, I., Bruix, J. & Reig, M., Apr 2019, In: *Journal of Hepatology*. 70, 1S, p. E599-E600 FRI-462.

**Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature**

Overby, A., Duval, L., Ladekarl, M., Laursen, B. E. & Donskov, F., Feb 2019, In: *Clinical genitourinary cancer*. 17, 1, p. e32-e37 6 p.

**T-cell-inflamed gene expression profile (GEP) and PD-L1 expression in patients (pts) with esophageal cancer (EC).**

Steiniche, T., Rha, S. Y., Chung, H. C., Georgsen, J. B., Ladekarl, M., Nordmark, M., Jespersen, M. L., Kim, H. S., Kim, H., Fein, C., Wu, T., Savage, M. J., Marton, M. J., Kang, S. P., Peter, S. A., Kelsen, D. P. & Ku, G. Y., 2019, In: *Journal of Clinical Oncology*. 37, Supl. 4, p. 26 1 p.

**Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)**

Ali, A. S., Grönberg, M., Langer, S. W., Ladekarl, M., Hjortland, G. O., Vestermark, L. W., Österlund, P., Welin, S., Grønbæk, H., Knigge, U., Sorbye, H. & Janson, E. T., 6 Mar 2018, In: *Medical Oncology*. 35, 4, p. 47

**Effects of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Goblet Cell Carcinoma: A Prospective Cohort Study**

Madsen, A. H., Ladekarl, M., Villadsen, G. E., Grønbæk, H., Sørensen, M. M., Stribolt, K., Verwaal, V. J. & Iversen, L. H., Feb 2018, In: *Annals of Surgical Oncology*. 25, 2, p. 422-430 9 p.

**Association of PD-L1 expression with prognosis among patients with 10 select cancers**

Steiniche, T., Ladekarl, M., Bæhr Georgsen, J., Andreasen, S., Busch-Sørensen, M., Zhou, W., Pruitt, S. K., Joe, A. K. & Liaw, K-L., 2018, In: *Annals of Oncology*. 29, Suppl. 8, p. viii15 53PD.

**Geographical Residency Influences Pancreatic Cancer Survival: A Danish Nationwide Population-based Cohort Study**

Kirkegård, J., Ladekarl, M., Fristrup, C., Hansen, C. P., Sall, M. & Mortensen, F. V., 2018.

**Urban versus rural residency and pancreatic cancer survival: A Danish nationwide population-based cohort study**

Kirkegård, J., Ladekarl, M., Fristrup, C. W., Hansen, C. P., Sall, M. & Mortensen, F. V., 2018, In: *PLOS ONE*. 13, 8, 11 p., e0202486.

**Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas**

Galleberg, R. B., Knigge, U., Tiensuu Janson, E., Vestermark, L. W., Haugvik, S-P., Ladekarl, M., Langer, S. W., Grønbæk, H., Österlund, P., Hjortland, G. O., Assmus, J., Tang, L., Perren, A. & Sorbye, H., Sep 2017, In: *European Journal of Surgical Oncology*. 43, 9, p. 1682-1689 8 p.

**Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma**

Ali, A. S., Grönberg, M., Federspiel, B., Scoazec, J-Y., Hjortland, G. O., Grønbæk, H., Ladekarl, M., Langer, S. W., Welin, S., Vestermark, L. W., Arola, J., Österlund, P., Knigge, U., Sorbye, H., Grimelius, L. & Janson, E. T., 2017, In: *P L o S One*. 12, 11, 15 p., e0187667.

**Danish Pancreatic Cancer Database**

Fristrup, C., Detlefsen, S., Hansen, C. P. & Ladekarl, M., 25 Oct 2016, In: *Clinical Epidemiology*. 8, p. 645-648 4 p.

**Diagnosis and treatment of bronchopulmonary neuroendocrine tumours: State of the art**

Tabaksblat, E. M., Langer, S. W., Knigge, U., Grønbæk, H., Mortensen, J., Petersen, R. H., Federspiel, B. H. & Ladekarl, M., Jan 2016, In: *Acta Oncologica*. 55, 1, p. 3-14 12 p.

**BRCA-associated pancreatico-biliary neoplasms: four cases illustrating the emerging clinical impact of genotyping**

Sharma, M. B., Carus, A., Sunde, L., Hamilton-Dutoit, S. & Ladekarl, M., 2016, In: *Acta Oncologica*. 55, 3, p. 377-381 5 p.

**A Nationwide Retrospective Study of Perioperative Chemotherapy for Gastroesophageal Adenocarcinoma: Tolerability, Outcome, and Prognostic Factors**

Larsen, A. C., Holländer, C., Duval, L., Schønnemann, K., Achiam, M., Pfeiffer, P., Yilmaz, M. K., Thorlacius-Ussing, O., Bæksgaard, L. & Ladekarl, M., 2015, In: *Annals of Surgical Oncology*. 22, 5, p. 1540-1547

**Goblet cell carcinoids: characteristics of a Danish cohort of 83 patients**

Olsen, I. H., Holt, N., Langer, S. W., Hasselby, J. P., Grønbæk, H., Hillingsø, J., Mahmoud, M., Ladekarl, M., Iversen, L. H., Kjær, A., Federspiel, B. H. & Knigge, U., 2015, In: *PLOS ONE*. 10, 2, p. e0117627

**Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms**

Janson, E. T., Sorbye, H., Welin, S., Federspiel, B., Grønbæk, H., Hellman, P., Ladekarl, M., Langer, S. W., Mortensen, J., Schalin-Jäntti, C., Sundin, A., Sundlöv, A., Thiis-Evensen, E. & Knigge, U., Oct 2014, In: *Acta oncologica (Stockholm, Sweden)*. 53, 10, p. 1284-97 14 p.

**Postoperative but not preoperative treatment with Sorafenib inhibits liver regeneration in rats**

Andersen, K. J., Knudsen, A. R., Kannerup, A-S., Nyengaard, J. R., Hamilton-Dutoit, S. J., Ladekarl, M. & Mortensen, F. V., 15 Apr 2014.

**Danish experiences with FOLFIRINOX as first-line therapy in patients with inoperable pancreatic cancer**

Kræmer, P. C., Schmidt, H. H. & Ladekarl, M., Apr 2014, In: Danish Medical Journal. 61, 4, A4819.

**Strong Prognostic Value of Tumor-infiltrating Neutrophils and Lymphocytes Assessed by Automated Digital Image Analysis in Early Stage Cervical Cancer: A Comparator Study with Observer-assisted Stereological Assessments**

Carus, A., Donskov, F., Switten Nielsen, P., Hager, H., Nedergaard, B., Steiniche, T. & Ladekarl, M., 2014, In: The Journal of OncoPathology. 2, 2, p. 1-9 9 p.

**Tumour-associated CD66b + neutrophil count is an independent prognostic factor for recurrence in localised cervical cancer**

Carus, A., Ladekarl, M., Hager, H., Nedergaard, B. & Donskov, F., 1 May 2013, In: British Journal of Cancer. 108, 10, p. 2116-2122 7 p.

**Advanced hepatocellular carcinoma in adolescence associated with congenital cholestasis: A case description**

Ladekarl, M., Villadsen, G. E., Rudbeck, A. R., Aagenæs, Ø., Nielsen, J. E., Hamilton-Dutoit, S. & Nordmark, M., 1 Jan 2013, In: Case Reports in Oncology. 6, 1, p. 98-103 6 p.

**Baggrundsnotat for brug af langtidsvirkende somatostatinanaloger og GH-receptorantagonist til akromegali.**

Hangaard, J., Andersen, M., Laursen, T., Nielsen, E. H., Storm, T. L., Rasmussen, Å. K., Poulsen, P. L., Friberg, A., Ladekarl, M., Schaffalitzky de Muckadell, O. B., Wilson, B., Knigge, U. P. & Grønnebæk, H., 2013, *Baggrundsnotat for brug af langtidsvirkende somatostatinanaloger og GH-receptorantagonist til akromegali.*

**Baggrundsnotat for brug af langtidsvirkende somatostatinanaloger til neuroendokrine tumorer**

Knigge, U. P., Grønnebæk, H., Ladekarl, M., Schaffalitzky de Muckadell, O. B., Wilson, B., Hangaard, J., Andersen, M., Laursen, T., Friberg, A., Nielsen, E. H., Storm, T. L., Rasmussen, Å. K. & Poulsen, P. L., 2013, *Baggrundsnotat for brug af langtidsvirkende somatostatinanaloger til neuroendokrine tumorer.* 13 p.

**Diffuse abdominal splenosis mimicking peritoneal metastases in a 35-year-old man with a resectable carcinoma of the ampulla of Vater**

Sorensen, S. F., Mortensen, F. V., Hellberg, Y. & Ladekarl, M., 2013, In: Case Reports in Oncology. 6, 3, p. 467-71 5 p.

**Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia**

Carus, A., Gurney, H., GebSKI, V., Harnett, P., Hui, R., Kefford, R., Wilcken, N., Ladekarl, M., Maase, H. V. D. & Donskov, F., 2013, In: Journal of Translational Medicine. 11, 8, 10 p., 189.

**Sorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerability**

Køstner, A. H., Sørensen, M., Olesen, R. K., Grønnebæk, H., Lassen, U. & Ladekarl, M., 2013, In: Scientific World Journal. 2013, p. 931972

**Sorafenib inhibits liver regeneration in rats**

Andersen, K. J., Knudsen, A. R., Kannerup, A-S., Sasanuma, H., Nyengaard, J. R., Hamilton-Dutoit, S. J., Ladekarl, M. & Mortensen, F. V., 2013.

**Tumor-associated CD66b+neutrophil and CD8+lymphocyte densities as independent prognostic factors for recurrence in localized cervical cancer: Automated digital image analysis and observer-assisted stereological assessments**

Carus, A., Ladekarl, M., Nielsen, P. S., Hager, H., Nedergaard, B. S., Steiniche, T. & Donskov, F., 2013, In: Journal of Clinical Oncology. 31, 15, suppl.

**Tumor-associated neutrophils and macrophages in non-small cell lung cancer: no immediate impact on patient outcome**

Carus, A., Ladekarl, M., Hager, H., Pilegaard, H., Switten Nielsen, P. & Donskov, F., 2013, In: Lung Cancer. 81, 1, p. 130-137 8 p.

**Blood and tumor inflammation markers in non-small cell lung cancer (NSCLC): Blood leukocytosis as an independent risk factor in early stage**

Carus, A., Ladekarl, M., Hager, H., Pilegaard, H., Switten Nielsen, P. & Donskov, F., 2012, In: Journal of Clinical Oncology. 30, Suppl. 15, 1 p., e21110.

**Dansk Pancreas Cancer Database**

Fristrup, C., Palnæs Hansen, C., Ladekarl, M. & Mortensen, M. B., 2012, In: Ugeskrift for Læger. 174, 42, p. 2545 1 p.

**Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers**

Rohrberg, K. S., Olesen, R. K., Pfeiffer, P., Ladekarl, M., Pappot, H., Christensen, I. J., Høyer-Hansen, G., Sørensen, M., Skov, B. G., Buysschaert, I., Carmeliet, P. & Lassen, U., 2012, In: Acta Oncologica. 51, 2, p. 234-42 9 p.

**Malignant pheochromocytoma and paraganglioma: Three cases illustrating the use of molecular targeted diagnostics and therapy and possible role of new drugs**

Zukauskaitė, R., Hjorthgau, K., Poulsen, P. L., Baerentzen, S. & Ladekarl, M., 30 Jun 2011, In: Acta Oncologica. 50, 8, p. 1255-9 5 p.

**Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab**

Rohrberg, K. S., Pappot, H., Lassen, U., Westman, M., Olesen, R. K., Pfeiffer, P., Ladekarl, M., Sørensen, M., Christensen, I. J. & Skov, B. G., 2011, In: Cancer Biology & Therapy. 11, 8, p. 732-9 8 p.

**Ovariemetastaser fra ventrikelcancer diagnosticeret med diffusionsvægtet 3T-magnetisk resonans-skanning**

Røhl, L., Nellemann, H. M., Ladekarl, M. & Pedersen, E. M., 2011, In: Ugeskrift for Læger. 173, 16-17, p. 1212-3 2 p.

**Toxicity-adjusted dose (TAD) administration of chemotherapy: Effect of baseline and nadir neutrophil count in patients with breast, ovarian, and lung cancer?**

Carus, A., Donskov, F., GebSKI, V., Kefford, R., Wilcken, N., Hui, R., Harnett, P., Ladekarl, M., Maase, H. V. D. & Gurney, H., 2011, In: Journal of Clinical Oncology. 29, Suppl. 15, 1 p., e21023.

**Onkologisk behandling af patienter med pancreascancer**

Ladekarl, M., Jensen, B. V. & Pfeiffer, P., 3 May 2010, In: Ugeskrift for Læger. 172, 18, p. 1373-6 4 p.

**A comparative study of the cellular immune response in patients with stage IB cervical squamous cell carcinoma. Low numbers of several immune cell subtypes are strongly associated with relapse of disease within 5 years**

Nedergaard, B., Ladekarl, M., Nyengaard, J. R. & Nielsen, K., 2008, In: Gynecologic Oncology. 108, 1, p. 106-111 6 p.

**Low density of CD3+, CD4+ and CD8+ cells is associated with increased risk of relapse in squamous cell cervical cancer**

Nedergaard, B., Ladekarl, M., Thomsen, H. F., Nyengaard, J. R. & Nielsen, K., 2008. 1 p.

**Low density of CD3+, CD4+ and CD8+ cells is associated with increased risk of relapse in squamous cell cervical cancer**

Nedergaard, B. S., Ladekarl, M., Thomsen, H. F., Nyengaard, J. R. & Nielsen, K., 2007, In: British Journal of Cancer. 97, 8, p. 1135-1138 4 p.

**Stereologic estimation of the total numbers, the composition and the anatomic distribution of lymphocytes in cone biopsies from patients with stage I squamous cell carcinoma of the cervix uteri**

Nedergaard, B., Nielsen, K., Nyengaard, J. R. & Ladekarl, M., 2007, In: Acta Pathologica Microbiologica et Immunologica Scandinavica. 115, 12, p. 1321-30 9 p.

**Choice of Methodology for Quantifying Cancer Structures in Tissue Sections: A Comparison of 2- and 3-Dimensional Estimators of Mitotic Activity, Cellularity and Nuclear Size in Breast Cancer**

Ladekarl, M., Apr 2004, In: Analytical and quantitative cytology and histology. 26, 2, p. 97-104 8 p.

**Detection of circulating tumour lysate-reactive CD4+ T cells in melanoma patients**

Ladekarl, M., Agger, R., Fleischer, C. C., Hokland, M., Hulgaard, E. F., Kirkin, A., von der Maase, H., Petersen, M. S., Rytter, C., Zeuthen, J. & Gundersen, H. J. G., 2004, In: Cancer Immunology, Immunotherapy. 53, p. 560-566 7 p.



**Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas**  
Nordmark, M., Loncaster, J., Aquino-Parsons, C., Chou, S-C., Ladekarl, M., Havsteen, H., Lindegaard, J. C., Davidson, S. E., Varia, M., West, C., Hunter, R., Overgaard, J. & Raleigh, J. A., Apr 2003, In: Radiotherapy & Oncology. 67, 1, p. 35-44 10 p.

**Nye behandlingsperspektiver ved duktalt carcinoma in situ mammae: New therapeutic perspectives in breast ductal carcinoma in situ**

Ladekarl, M., Grau, C. & Andersen, J., 2001, In: Ugeskrift for Læger. 163, 37, p. 5014-5017 4 p., 4979.

**The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors**

Horsman, M. R., Ehrnrooth, E., Ladekarl, M. & Overgaard, J., 1 Nov 1998, In: International Journal of Radiation Oncology, Biology, Physics. 42, 4, p. 895-898 4 p.

**Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas**

Jensen, V., Sørensen, F. B., Bentzen, S. M., Ladekarl, M., Nielsen, O. S., Keller, J. & Jensen, O. M., Jun 1998, In: Histopathology. 32, 6, p. 536-46 11 p.

**Objective malignancy grading: A review emphasizing unbiased stereology applied to breast tumors**

Ladekarl, M., 1998, In: APMIS, Supplement. 106, Suppl. 79, p. 5-34 30 p.

**Total number of cancer cell nuclei and mitoses in breast tumors estimated by the optical disector**

Ladekarl, M., Jensen, V. & Nielsen, B., Aug 1997, In: Analytical and quantitative cytology and histology. 19, 4, p. 329-337 9 p.

**The prognostic value of MIB-2 and bcl-2 expression in soft tissue sarcomas.**

Jensen, V., Sørensen, F. B., Ladekarl, M., Nielsen, O. S. & Jensen, O. M., Mar 1996.

**The prognostic value of quantitative histopathology in soft tissue fibrosarcomas.**

Ladekarl, M., Jensen, V., Sørensen, F. B., Nielsen, O. S. & Jensen, O. M., Mar 1996.

**The prognostic value of quantitative histopathology in soft tissue malignant fibrous histiocytomas.**

Sørensen, F. B., Jensen, V., Ladekarl, M., Nielsen, O. S. & Jensen, O. M., Mar 1996.

**Objektiv histologisk gradering af planocellulær og adenokvæmøs lungecancer**

Ladekarl, M., Hansen, T. B., Nielsen, R. H., Mouritzen, C., Henriques, U. & Sørensen, F. B., 1996, In: Ugeskrift for læger. 158, 40, p. 5611-5615 5 p.

**Stereologic estimation of breast tumor size**

Ladekarl, M., Jensen, V. & Nielsen, B., 1996, In: Analytical and quantitative cytology and histology. 18, 2, p. 151-157 7 p.

**Quantitative histopathology in lymph node-negative breast cancer. Prognostic significance of mitotic counts**

Ladekarl, M. & Jensen, V., Nov 1995, In: Virchows Archiv. 427, 3, p. 265-270 6 p.

**Objective malignancy grading of squamous cell carcinoma of the lung. Stereologic estimates of mean nuclear size are of prognostic value, independent of clinical stage of disease**

Ladekarl, M., Bøek-Hansen, T., Henrik-Nielsen, R., Mouritzen, C., Henriques, U. & Sørensen, F. B., 1 Sep 1995, In: Cancer. 76, 5, p. 797-802 6 p.

**The prognostic value of oncogenic antigen 519 (OA-519) expression and proliferative activity detected by antibody MIB-1 in node-negative breast cancer**

Jensen, V., Ladekarl, M., Holm-Nielsen, P., Melsen, F. & Sørensen, F. B., Aug 1995, In: Journal of Pathology. 176, 4, p. 343-352 10 p.

**Quantitative histopathology in ductal carcinoma of the breast. Prognostic value of mean nuclear size and mitotic counts**  
Ladekarl, M., 15 Apr 1995, In: Cancer. 75, 8, p. 2114-2122 9 p.

**Significance of variations in section mounting technique for nuclear stereology and morphology in urinary bladder neoplasms**

Ladekarl, M. & Svanholm, H., Mar 1995, In: APMIS. 103, 7-8, p. 892-896 5 p.

**Immunohistochemical quantitation of oestrogen receptors and proliferative activity in oestrogen receptor positive breast cancer**

Jensen, V. & Ladekarl, M., 1995, In: Journal of Clinical Pathology. 48, 5, p. 429-432 4 p.

**The influence of tissue processing on quantitative histopathology in breast cancer**

Ladekarl, M., May 1994, In: Journal of Microscopy. 174, 2, p. 93-100 8 p.

**Reproducibility of mean nuclear volume and correlation with mean nuclear area in breast cancer: An investigation of various sampling schemes**

Baak, J. P. A., Ladekarl, M. & Sørensen, F. B., Jan 1994, In: Human Pathology. 25, 1, p. 80-85 6 p.

**Quantitative histopathological variables in in situ and invasive ductal and lobular carcinomas of the breast**

Ladekarl, M. & Sørensen, F. B., Dec 1993, In: APMIS : Acta pathologica, microbiologica et immunologica Scandinavica. Supplementum. 101, 12, p. 895-903 9 p.

**Prognostic, quantitative histopathologic variables in lobular carcinoma of the breast**

Ladekarl, M. & Sørensen, F. B., 1 Nov 1993, In: Cancer. 72, 9, p. 2602-2611 10 p.

**Prognostic value of nucleolar size and size pleomorphism in choroidal melanomas**

Sørensen, F. B., Gamel, J. W., Jensen, O. A., Ladekarl, M. & McCurdy, J., May 1993, In: APMIS : Acta pathologica, microbiologica et immunologica Scandinavica. Supplementum. 101, 5, p. 358-68 11 p.

## Press/Media

### 10 afklarende svar fra kræftlægen

Morten Ladekarl

28/05/2020

1 Media contribution

### Behandling af kræft i bugspytkirtlen

Morten Ladekarl

07/10/2022

1 item of Media coverage

### Danske kræftafdelinger behandler bugspytkirtelkræft forskelligt, og det påvirker levetiden

Morten Ladekarl

16/03/2022 → 23/03/2022

4 items of Media coverage

### Endnu en KRAS-hæmmer: Lovende effekt mod ikke-småcellet lungekræft

Morten Ladekarl

13/04/2021

1 item of Media coverage

**Flere kræftpatienter vil have gavn af upfront gensekventering**

Morten Ladekarl

20/09/2020 → 21/09/2020

2 items of Media coverage

**Formand for kræftlæger: Vi venter stadig på biomarkørernes store gennembrud**

Morten Ladekarl

04/12/2019

1 item of Media coverage

**Forskere vil afprøve immunterapi og elektriske impulser mod bugspytkirtelkræft**

Morten Ladekarl

06/07/2020

1 item of Media coverage

**Forskere vil afprøve immunterapi og elektriske impulser mod bugspytkirtelkræft**

Morten Ladekarl

01/09/2020

2 items of Media coverage

**Første gang nogensinde: KRAS-hæmmer med tydelig effekt**

Morten Ladekarl

21/10/2020

1 item of Media coverage

**Første overlevelsesresultater for KRAS-hæmmer mod lungekræft er flotte, men**

Morten Ladekarl

14/06/2021

1 item of Media coverage

**KRAS-hæmmer viser lovende effekt mod tarmkræft**

Morten Ladekarl

21/09/2021

1 item of Media coverage

**Kræftens Bekæmpelse uddeler støtte til kræftforskning**

Morten Ladekarl

19/08/2020 → 21/08/2020

4 items of Media coverage

**Kræftlægen har ordet**

Morten Ladekarl

28/05/2020

1 item of Media coverage

**Læger håber på en ny kategori i kræftbehandlingen**

Morten Ladekarl

22/01/2021

1 item of Media coverage

**Morten Ladekarl er ny professor i onkologi**

Morten Ladekarl

17/01/2019 → 17/01/2019

2 items of Media coverage

### **Nye overlevelsesdata styrker optimisme om KRAS-hæmmer mod lungekræft**

Morten Ladekarl

18/05/2022

1 item of Media coverage

### **Nyt om navne**

Morten Ladekarl

28/01/2019

1 item of Media coverage

### **Nyt studie: KRAS-hæmmer viser igen lovende effekt mod KRAS-muteret NSCLC**

Morten Ladekarl

02/02/2021

1 item of Media coverage

### **Potentielt praksisændrende: Nyt antistof øger overlevelsen mod kræft i mavesæk og mavemund**

Morten Ladekarl

23/01/2023 → 24/01/2023

2 items of Media coverage

### **SPØRG OS**

Morten Ladekarl

17/02/2022

1 item of Media coverage

### **Succes med RAS-hæmmer giver håb om en ny kategori af kræftbehandlinger**

Morten Ladekarl

10/01/2021

1 item of Media coverage

### **Aalborg Universitetshospital indfører personaliseret kræftbehandling**

Morten Ladekarl

18/11/2020

1 item of Media coverage

## **Projects**

### **EPIC-1: A phase II Study of Electroporation Potentiated Immunotherapy in Liver Metastatic Pancreatic Cancer**

Flak, R. V., Ladekarl, M., Poulsen, L. Ø., Thorlacius-Ussing, O., Stender, M. T., Detlefsen, S., Agger, R., Kofod-Olsen, E. & Wanders, A.

01/01/2021 → 31/12/2025

## **Research profile**

Clinical trials; targeted therapy; genomics; diagnostics; cancer immunology, pathology and epidemiology; gastrointestinal and rare cancers.

## **Leadership**

Professor in oncology and precision medicine, Aalborg (2019-). Former head of GI cancer section and Unit for Experimental Cancer Treatment, Aarhus University Hospital. Member of NBH expert committee for experimental cancer treatment (2015-). Member of Danish Medical Medicines Councils advisory board (2014-). Board member of national multidisciplinary groups for pancreatic, hepato-biliary and gastro-esophageal tumors. Member of the Danish Comprehensive Cancer Center steering committee (2021-), and the ctDNA Center steering committee (2020-). Member of National Genome Center advisory boards (2021-). Chair of one international and three regional scientific meetings.

## **Current clinical trials**

PI of Proseq study of personalized medicine  
EPIC-1 trial (NCT04835402) of immunotherapy in pancreatic cancer  
Pantax Ib trial (NCT04652206) targeting therapy resistance in pancreatic cancer  
DPCG-01 randomized trial of chemotherapy in fragile patients with pancreatic cancer.

## **Supervisor and Examiner Responsibilities**

Prior supervisor for 2 PhD-students at Health, University of Aarhus.  
Current supervisor for 3 PhD-students at Health, University of Aalborg.  
Member/head of the evaluation committee for 7 PhD and 2 doctoral dissertations.

## **Application reviews**

Protocol reviews for EORTC, the Dutch Research Council (NWO) and EU.

## **Research grants**

Active grants from Danish Cancer Society, Danish Regions, Brogaards Foundation, Scandion Oncology A/S, and the NBH.

## **Scientific Journal Involvement**

Member of reviewer board for Journal of Cancers.  
Advisory board member of Framingham on HCC (2008-12).  
Guest editor for Scientific World Journal (2012) and Journal of Clinical Medicine (2021).  
More than 37 peer reviews for at least 14 different international journals.